- Home
- ORMP vs TLSA Comparison
ORMP vs TLSA Comparison
Compare ORMP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | TLSA |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 164.1M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ORMP | TLSA |
|---|---|---|
| Price | $4.10 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 181.1K | ★ 200.0K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.92 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.14 |
| 52 Week High | $5.01 | $2.60 |
Technical Indicators
Market Signals| Indicator | ORMP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 55.53 |
| Support Level | $3.83 | $1.23 |
| Resistance Level | $4.22 | $1.54 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 13.56 | 35.36 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.